- Bristol-Myers Squibb (NYSE:BMY) enters into a clinical trial collaboration with Tokyo-based Kyowa Hakko Kirin to conduct a U.S.-based Phase 1/2 combination study of Kyowa's Poteligeo (mogamulizumab) and Bristol-Myers' Opdivo (nivolumab) in patients with advanced or metastatic solid tumors. The study will be conducted by Kyowa.
- The combination is also being evaluated in Japan per a previous agreement.
- Mogamulizumab in a humanized monoclonal antibody directed against CC chemokine receptor type 4 (CCR4). It was launched in Japan in May 2012 for the treatment of relapse/refractory CCR4-positive adult T-cell leukemia-lymphoma.
- Nivolumab is a programmed death-1 (PD-1) immune checkpoint inhibitor that is approved in the U.S. for the treatment of metastatic squamous non-small cell lung cancer and metastatic melanoma.